FDA weighs whether to publicize inspection reports
This article was originally published in The Silver Sheet
Executive Summary
FDA is seeking input via its Transparency Blog about whether it should publicly disclose key findings from FDA-483 inspection report forms. The reports typically are not made public. Processing Freedom of Information Act requests for the reports can take a long time because of the need to redact confidential trade secret information, the agency notes. FDA says the reports could be redesigned to separate out a summary or key-findings page that could quickly be made publicly available. The blog is found at http://fdatransparencyblog.fda.gov